Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S157000, C546S167000, C546S153000, C514S314000
Reexamination Certificate
active
06852733
ABSTRACT:
NHE-1 inhibitor, methods of using the NHE-1 inhibitor and pharmaceutical compositions containing the NHE-1 inhibitor. The NHE-1 inhibitor is useful for the reduction of tissue damage resulting from tissue ischemia.
REFERENCES:
patent: 6492401 (2002-12-01), Hamenaka
patent: 1101763 (2001-05-01), None
patent: 9826803 (1998-06-01), None
patent: WO 9827061 (1998-06-01), None
patent: WO 9935137 (1999-07-01), None
patent: WO 9943663 (1999-09-01), None
Principles of Pharamacology. Basic Concepts & Clinical Applications. (1995) Edited by Munson et al. Chapman & Hall. pp. 52-56.*
Beedham et al. Drug Metabolism and Disposition. (Nov.-Dec. 1992) 20(6), 889-95.*
Beedham C et al. Drug Metablism and Disposition. 1992, 20(6), 889-895.*
W.J. Ehlhardt et al., Drug Metab. & Dispo., 26, No, 1, 42-51 (1998).
Chen Weichao G.
Cox Eric D.
Guzman-Perez Angel
Ashbrook Charles
Engelmann John H.
Huang Evelyn Mei
Pfizer Inc.
Richardson Peter C.
LandOfFree
Sodium-hydrogen exchanger type 1 inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sodium-hydrogen exchanger type 1 inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sodium-hydrogen exchanger type 1 inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448460